Higher-dose venlafaxine — Competitive Intelligence Brief

Higher-dose venlafaxine (Higher-dose venlafaxine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin-norepinephrine reuptake inhibitor (SNRI). Area: Psychiatry/Mental Health.

marketed Serotonin-norepinephrine reuptake inhibitor (SNRI) Serotonin transporter (SERT), norepinephrine transporter (NET) Psychiatry/Mental Health Small molecule

Target snapshot

Higher-dose venlafaxine (Higher-dose venlafaxine) — University of Pittsburgh. Higher-dose venlafaxine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their synaptic availability.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Higher-dose venlafaxine TARGET	Higher-dose venlafaxine	University of Pittsburgh	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT), norepinephrine transporter (NET)
Pristiq	Desvenlafaxine Succinate	Pfizer	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin and norepinephrine reuptake	2008-01-01
Effexor	Venlafaxine Hydrochloride	Pfizer	marketed	Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)	Serotonin and norepinephrine reuptake transporters	1993-01-01
toludesvenlafaxine hydrochloride sustained-release tablets	toludesvenlafaxine hydrochloride sustained-release tablets	Shanghai Mental Health Center	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT) and norepinephrine transporter (NET)
Aripiprazole + desvenlafaxine succinate sustained release	Aripiprazole + desvenlafaxine succinate sustained release	Pfizer	marketed	Atypical antipsychotic + serotonin-norepinephrine reuptake inhibitor (SNRI) combination	Dopamine D2/D3 receptors (aripiprazole); serotonin transporter (SERT) and norepinephrine transporter (NET) (desvenlafaxine)
Treatment (Viibryd)	Treatment (Viibryd)	Southern California Institute for Research and Education	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI) with 5-HT1A partial agonist activity	Serotonin transporter (SERT); 5-HT1A receptor (partial agonist)
Drug treatment with Cymbalta	Drug treatment with Cymbalta	Jefferson Clinic, P.C.	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin and norepinephrine transporters

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serotonin-norepinephrine reuptake inhibitor (SNRI) class)

1. Pfizer · 3 drugs in this class
2. Wyeth is now a wholly owned subsidiary of Pfizer · 3 drugs in this class
3. National Institute of Mental Health (NIMH) · 2 drugs in this class
4. Zhejiang Huahai Pharmaceutical Co., Ltd. · 2 drugs in this class
5. Eli Lilly and Company · 2 drugs in this class
6. New York State Psychiatric Institute · 1 drug in this class
7. North Dakota State University · 1 drug in this class
8. Ministry of Health & Welfare, Korea · 1 drug in this class
9. Purdue Pharma, Canada · 1 drug in this class
10. Shanghai Mental Health Center · 1 drug in this class